Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
• Maximum Potential Dilution of Approximately 23.04%, Based on Share Capital of Cellectis as of September 30, 2022 NEW YORK, Jan. 04, 2023 -- Cellectis S.A. , a clinical-stage... | January 4, 2023
Source: marketscreener.com